News Posts List

PINEHURST, NC – The winners of Southeast BIO’s (SEBIO) Deal of the Year awards were announced in a ceremony held at its 19th Annual Investor Forum in Pinehurst, North Carolina on November 15, 2017. Companies competed in the following categories:

• IPO
• VC Transaction
• Initial Funding
• Strategic Transaction
• Strategic Investment
• SEBIO Leadership Award

“Southeast BIO’s Awards Program recognizes the companies and individuals that are driving the growth of the Southeast’s life sciences industry,” said David Day, Executive Director, SEBIO. “SEBIO award winners are a measure of the strong companies, exciting new technologies, and executive leadership contributing to the development of a robust industry across the region.”

The winners of the 2017 Deal of the Year Awards are:

G1 Therapeutics, a Research Triangle-based clinical-stage oncology company, for the SEBIO Deal of the Year: IPO. G1 Therapeutics, became a publicly traded company in May with a $105 million initial public offering of seven million shares of stock priced at $15 a share. G1, a spinout from the University of North Carolina at Chapel Hill, is developing novel therapies that address significant unmet needs in people with various cancers. 

NeuroTronik a medical technology company based in Research Triangle Park, N.C. and Dublin, Ireland for the SEBIO Deal of the Year: Strategic Investment. NeuroTronik Limited and NeuroTronik, Inc. announced closing on a $23.1 million Series B Preferred Stock Financing, tranched in line with project plan milestones. The funding was led by Boston Scientific Group, plc. Other major investors include Hatteras Venture Partners, Synergy Life Science Partners, Lord Baltimore Investment Partners, Mountain Group Capital, and Sovereign’s Capital.

Femasys, Inc., a developer of innovative medical devices based in Atlanta, Georgia, for the SEBIO Deal of the Year: VC Transaction.  In December, 2016, Femasys closed $40 million in Series C financing.  The transaction was arranged by Salem Partners, a Los Angeles-based investment bank which also participated as a principal investor.

HemoShear Therapeutics, LLC, a drug-discovery company based in Charlottesville, VA., for the SEBIO Deal of the Year: Strategic Transaction.  Takeda Pharmaceutical Company Limited (TSE: 4502) and HemoShear Therapeutics, LLC, a privately held biotechnology company, announced a partnership to discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH).

Intezyne Technologies, a Tampa, FL.-based clinical-stage oncology company focused on cancer therapies, for the SEBIO Deal of the Year: Initial Funding. Intezyne Technologies raised $10 million in an oversubscribed Series A round led by Gaston Capital. McAllister said Intezyne has just launched a $30 million pre-IPO Series B Preferred round which he plans to close by mid-2018.

Ken Tindall for the SEBIO Leadership Award. Ken Tindall is a responsible for the North Carolina Biotechnology Center’s Science and Business Development efforts, which include the Business and Technology Development, the Science and Technology Development, and the Centers of Innovation programs as well as Library and Information Technology. These programs currently administer 10 grants or loans and since 2000 have provided more than $87 million in support of North Carolina research, educational activities and biotechnology businesses. As for Ken’s service to SEBIO, simply put, he has done everything for SEBIO that has been asked of him and more. Ken has served on the Board for a very long time. He has chaired the conference, led the raising of sponsorship dollars and provided wise leadership over the years. 

 The 2018 SEBIO Awards Ceremony will be held in November during the 20th Annual Southeast BIO Investor Forum in Atlanta, Georgia. Further details coming early 2018.

About Southeast BIO

Southeast BIO (SEBIO) is a regional nonprofit organization that fosters the growth of the life sciences industry in the Southeastern United States through efforts that promote entrepreneurship and bring together the key players active in the development of the industry. SEBIO’s geographic footprint includes Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee and Virginia. SEBIO focuses on key industries within the life sciences, including: bio/pharma, medical devices and technology, agricultural biotechnology, animal health, bioinformatics and biomaterials. Visit www.sebio.org for more information.

http://ow.ly/vdR730gFceD